Welcome to our dedicated page for Bio-Techne SEC filings (Ticker: TECH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bio-Techne Corporation filings document the formal disclosure record for a Minnesota life sciences company that sells reagents, analytical instruments and precision diagnostics. Recent Form 8-K reports furnish quarterly and annual operating results, financial condition updates and cash dividend announcements, with exhibits containing the related earnings and dividend releases.
Governance filings include definitive proxy materials and annual meeting vote results covering board size and director elections. Other current reports disclose executive leadership changes and employment arrangements for segment management, tying corporate governance disclosures to Bio-Techne's diagnostics, spatial biology and analytical solutions operations.
Robert V. Baumgartner, a director of Bio-Techne Corporation (TECH), reported transactions on 08/25/2025 in which he exercised 17,040 stock options with an exercise price of $21.84 and immediately sold 17,040 common shares at a weighted average price of $56.21 (sales ranged $55.97–$56.34). The Form 4 shows a temporary increase in beneficial ownership to 61,903 shares after the exercise, and a final beneficial ownership of 44,863 shares following the sale. The filing lists outstanding stock options across multiple grant years with strike prices from $21.84 to $128.81 and various expiration dates, and notes one option vests on the earlier of the one-year anniversary of the 10/24/2024 grant or Bio-Techne's 2025 annual meeting. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Baumgartner.
Form 144 filed for Bio-Techne Corp. (TECH) reports a proposed sale of 17,040 common shares via Morgan Stanley Smith Barney LLC on 08/25/2025. The filing shows an aggregate market value of $960,388.03 and notes 155,549,587 shares outstanding, indicating the sale represents a very small fraction of the company’s outstanding stock. The shares were acquired and paid for on 08/25/2025 through a stock option exercise paid in cash. The filer certifies they are not aware of undisclosed material adverse information. No other sales in the past three months are reported.
Form 144 notice for Bio-Techne Corp. (TECH) reports a proposed sale of 17,040 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $957,849.07. The filing shows the shares outstanding are 155,549,587 and lists the approximate sale date as 08/25/2025 on NASDAQ. The securities were acquired on 08/25/2025 by exercise of options under a registered plan from the issuer and payment is shown as cash. The filer represents they are not aware of undisclosed material adverse information. Several identifying fields such as the filer name/CIK and issuer address are not provided in the text.
Bio-Techne (TECH) describes fiscal 2025 operational and strategic developments including portfolio expansion, tax attributes, and governance controls. The company reports 155,549,587 shares outstanding (post 4-for-1 split adjustment) and an independent opinion that it maintained effective internal control over financial reporting as of June 30, 2025 under the COSO 2013 framework.
Material acquisitions noted include Lunaphore acquired for $169.7 million (cash-free, debt-free) adding spatial biology instruments to Diagnostics and Spatial Biology, and Namocell acquired for $101.2 million net of cash plus up to $25 million contingent consideration, adding single-cell sorting platforms to Protein Sciences. The company recorded goodwill related to these deals that is not deductible for tax purposes. The filing discloses a $37.2 million arbitration settlement (inclusive of interest and fees) and an additional $0.5 million payment related to an options dispute.
James Hippel, Chief Financial Officer of Bio-Techne Corporation (TECH), reported transactions on 08/15/2025. The Form 4 shows a purchase/vest of 4,010 restricted stock units or similar awards (Code M) at $0 and a disposition of 1,926 shares at $53.60 each. After these transactions the reported beneficial ownership of common stock is 129,883 shares. The filing also lists extensive derivative holdings: multiple stock option grants and restricted or performance-based stock units totaling tens of thousands of underlying shares (for example, 186,068, 167,328, 37,632 and other position sizes as detailed in Table II). The form is signed by an attorney-in-fact on behalf of Mr. Hippel.
Amy E. Herr, a director of Bio-Techne Corp (TECH), reported multiple transactions dated 08/15/2025 affecting both her direct and indirect holdings. The filing shows disposals of 1,040 shares (reported as a direct disposition) and 101 shares sold at $53.60 (reported as indirect, by significant other). The report also records a non-cash acquisition of 279 shares (transaction code M) at $0 and various option and restricted stock unit holdings and vesting schedules. After the reported transactions, beneficial ownership totals are shown as 2,255 and 2,154 shares in different lines, with numerous outstanding stock options and RSUs exercisable or vesting through 2035.
Kim Kelderman, CEO and Director of Bio-Techne Corp (TECH), reported multiple equity transactions dated 08/15/2025. The filing shows a grant/award of 8,543 restricted stock units and an acquisition of 35,354 restricted stock units and 70,708 performance restricted stock units (all reported as acquisitions at $0), plus an acquisition of 90,441 stock options exercisable at $53.60 with an 08/15/2035 expiration.
The report also discloses a sale of 4,305 shares of common stock at $53.60 and a prior acquisition of 8,543 shares (code M) resulting in 55,273 shares beneficially owned after the transactions. Numerous outstanding stock options and performance awards with varying exercise prices and vesting/expiration schedules are listed.
Shane Bohnen, SVP – General Counsel of Bio-Techne Corp (TECH), reported multiple option exercises, restricted stock unit vesting events and a small sale on 08/15/2025. The Form 4 shows a non-derivative acquisition of 1,718 shares (transaction code M) at $0 and a sale of 527 shares at $53.60, leaving 4,385 shares beneficially owned after the sale. The filing details many derivative holdings: several stock options exercisable at strike prices from $47.60 to $120.46, totaling tens of thousands of underlying shares, plus multiple restricted stock unit and performance award pools. Notable items include exercises or acquisitions that increased holdings by large blocks of shares via option-related transactions and performance awards that vest on future dates if goals are met.
Matthew McManus, President – Diag & Spatial Bio at Bio-Techne Corp (TECH), reported transactions dated 08/15/2025. He was granted 2,637 restricted stock units (non-derivative, code M) at $0 and reported a sale/disposition of 880 shares at $53.60 (code F), leaving 4,735 shares owned after the sale. The filing lists numerous derivative holdings and awards including performance restricted stock units, restricted stock units and stock options with exercise prices of $68.54, $74.91 and $53.60. Aggregate derivative positions include named totals such as 24,614, 21,320, 19,243, 15,902, 15,825, and 9,241 underlying shares across options and RSUs, with vesting schedules and performance-based vesting dates listed through 2035. The form is signed by Andrew Nick as attorney-in-fact dated 08/19/2025.
Bio-Techne Corp. (TECH) insider William Geist reported multiple equity transactions on 08/15/2025 reflecting compensation vesting and a small sale. The filing shows the acquisition of 2,623 common shares via vested restricted stock units at $0, and a disposition of 803 shares sold at $53.60, leaving 15,112 shares beneficially owned after the sale. The report also lists numerous outstanding stock options and performance-based awards, including 24,758 newly acquired stock options exercisable at $53.60 with an 08/15/2035 expiration, other options at strike prices from $74.91 to $100.39, and several restricted and performance RSU pools totaling tens of thousands of shares that vest on various future dates if conditions are met. Transactions were signed by an attorney-in-fact on 08/19/2025.